Start: 10 Nov 2021, 17:30
End: 10 Nov 2021, 18:30

Chair: Professor James Larkin, The Royal Marsden, UK
Speaker: Dr Ana Arance, Hospital Clínic Barcelona, Spain
Speaker: Dr John Haanen, The Netherlands Cancer Institute, Holland
Speaker: Professor Jessica Hassel, Heidelberg University, Germany
Speaker: Professor Inge Marie Svane, Center for Cancer Immune Therapy (CCIT), Denmark

This session will cover the status quo of immune-therapeutics, some of the key unanswered questions with their implications, and the issues/opportunities for the future of this area of research. Speakers will cover cellular therapy for solid tumours, targeting new checkpoints in the clinic, combination approaches, lessons learnt from failures, rational treatment of side effects, and if microbiome is clinically actionable in 2021. They’ll also cover the benefit/risks of CPI treatment in non-clinical trial eligible populations, and the use of immunosuppression to treat CPI side effects.

Session labels:

Clinicians Discovery / underpinning research Nurses Panel Patient experts Scientists Students Trainees / Early career researchers Treatment